Related references
Note: Only part of the references are listed.FXa variants advance toward a therapy for bleeding
Jonas Emsley
BLOOD (2015)
FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia
Ayako Nogami et al.
ONCOTARGET (2015)
Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia
N. Sandhoefer et al.
LEUKEMIA (2015)
A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML
Cheuk Him Man et al.
BLOOD (2014)
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
V. D'Amato et al.
BRITISH JOURNAL OF CANCER (2014)
SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia
Alexandre Puissant et al.
CANCER CELL (2014)
FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations
Sabine Kayser et al.
LEUKEMIA & LYMPHOMA (2014)
The PI3-kinase isoform p110δ is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner
J. Sun et al.
ONCOGENE (2014)
Deciphering Combinations of PI3K/AKT/mTOR Pathway Drugs Augmenting Anti-Angiogenic Efficacy In Vivo
Temitope Sasore et al.
PLOS ONE (2014)
A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
Brian C. Grabiner et al.
CANCER DISCOVERY (2014)
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD
Catherine C. Smith et al.
BLOOD (2013)
An Adaptive Alignment Algorithm for Quality-controlled Label-free LC-MS
Marianne Sandin et al.
MOLECULAR & CELLULAR PROTEOMICS (2013)
FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia
A. Y. H. Leung et al.
LEUKEMIA (2013)
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib
C. Albers et al.
LEUKEMIA (2013)
mTOR kinase structure, mechanism and regulation
Haijuan Yang et al.
NATURE (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
Cheuk Him Man et al.
BLOOD (2012)
PKI-587 and Sorafenib Targeting PI3K/AKT/mTOR and Ras/Raf/MAPK Pathways Synergistically Inhibit HCC Cell Proliferation
Roberto Gedaly et al.
JOURNAL OF SURGICAL RESEARCH (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
STEM CELL FACTOR RECEPTOR/c-KIT: FROM BASIC SCIENCE TO CLINICAL IMPLICATIONS
Johan Lennartsson et al.
PHYSIOLOGICAL REVIEWS (2012)
Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor
Robert Mallon et al.
CLINICAL CANCER RESEARCH (2011)
Characterization of the expression of HTm4 (MS4A3), a cell cycle regulator, in human peripheral blood cells and normal and malignant tissues
Jeffery L. Kutok et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2011)
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway
A. M. Martelli et al.
LEUKEMIA (2011)
Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells
Friedrich Stoelzel et al.
ANNALS OF HEMATOLOGY (2010)
AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2
Wei Wang et al.
BLOOD (2010)
Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (PKI-587), a Highly Efficacious Dual Inhibitor
Aranapakam M. Venkatesan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
Gunnar Juliusson et al.
BLOOD (2009)
A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML
Frank Breitenbuecher et al.
BLOOD (2009)
Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome
Bas J. Wouters et al.
BLOOD (2009)
FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro
Nikolas von Bubnoff et al.
CANCER RESEARCH (2009)
Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin
Ker Yu et al.
CANCER RESEARCH (2009)
Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3
Kristina Masson et al.
CELLULAR SIGNALLING (2009)
Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation
Elena Razumovskaya et al.
EXPERIMENTAL HEMATOLOGY (2009)
The Proteios Software Environment: An Extensible Multiuser Platform for Management and Analysis of Proteomics Data
Jari Hakkinen et al.
JOURNAL OF PROTEOME RESEARCH (2009)
Structural and numerical variation of FLT3/ITD in pediatric AML
Soheil Meshinchi et al.
BLOOD (2008)
The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases
Steven Knapper et al.
BLOOD (2006)
Identification of a novel VNTR polymorphism in C6orf37 and its association with colorectal cancer risk in Chinese population
Jing Cui et al.
CLINICA CHIMICA ACTA (2006)
Clinical significance of FLT3 in leukemia
H Kiyoi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2005)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
RM Stone et al.
BLOOD (2005)
Constitutive NF-kappa B DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway
KU Birkenkamp et al.
LEUKEMIA (2004)
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm
S Fröhling et al.
BLOOD (2002)
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia:: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
S Schnittger et al.
BLOOD (2002)
Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines
F Hayakawa et al.
ONCOGENE (2000)
Share Paper
